Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
May 08, 2024 06:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
May 07, 2024 06:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
March 27, 2024 06:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
March 20, 2024 06:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences to Present at the 36th Annual Roth Conference
March 14, 2024 08:52 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
March 04, 2024 06:40 ET
|
Cellectar Biosciences
Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients Durability of clinical activity achieved 67% Overall Survival and 42% Progression Free...
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024 06:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
January 30, 2024 06:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
January 25, 2024 06:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
January 22, 2024 06:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...